The company finished the March quarter with $21 million in the bank.
() has appointed Dr Jens Eckstein as a non-executive director to its board effective as of today.
Dr Eckstein is a leading biotechnology executive and managing partner of Apollo Ventures, a venture capital firm that invests in seed and early stage biotechnology companies.
He has more than 15 years venture capital experience funding early to clinical stage biopharmaceutical companies.
Imugene’s executive chairman Paul Hopper said: “Imugene continues to attract a world class team.
“We welcome Dr Eckstein to the board and look forward to working together to advance our highly promising cancer immuno therapy pipeline.”
Strong pipeline of cancer vaccines in development
The company has a strong pipeline of cancer vaccines in development.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE